Identification of Circular RNA Expression Profiles in White Adipocytes and Their Roles in Adipogenesis.
Peng-Peng Zhang, Qiu Han, Ming-Xuan Sheng...
https://pubmed.ncbi.nlm.nih.gov/34489740Actively Recruiting
All Genders
Healthy Volunteers
ID07512609
Environment, Inflammation and Metabolic Diseases Study
Led by Qifu Li · Updated on 2026-04-06
8000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying endocrine and metabolic diseases by creating a specialized database called the Chongqing Environment, Inflammation, and Metabolic Diseases Study (EIMDS). This observational study aims to build an early warning model based on environmental, genetic, and protein factors to uncover new mechanisms behind these diseases and identify new treatment targets. The cohort includes about 8,000 community members followed for over five years. Participants are grouped based on having hypertension, diabetes mellitus, or autonomous aldosterone secretion (AAS). The study involves baseline biochemical screenings, including tests measuring plasma aldosterone and renin levels to classify AAS. No experimental treatments are given; instead, participants continue their usual clinical care while undergoing standardized assessments and biospecimen collections for advanced molecular analyses. During the study, participants undergo clinical, biochemical, and event assessments every two years, with blood and urine samples collected for research. The primary outcome is to determine the prevalence of AAS over a five-year follow-up. Secondary outcomes include identifying risk factors, exploring associations between AAS and kidney or metabolic disorders, and screening for key proteins and biomarkers. The study helps understand disease progression through detailed molecular and clinical data gathered over time.
CONDITIONS
Brief Title
Environment, Inflammation and Metabolic Diseases Study
Who Can Participate
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Individuals who voluntarily participate in the physical examination
You will not qualify if you...
- Participants with incomplete data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo baseline biochemical screening and standardized assessments including measurement of plasma aldosterone concentration, plasma renin concentration, and collection of demographic, clinical, biochemical, anthropometric data and biospecimens for proteomic analysis.
1 visit (in-person)
Long-term Monitoring
Duration - Approximately 5 years
Participants are followed up every two years for clinical, biochemical, and endpoint event assessments, including collection of blood and urine samples to explore risk factors and molecular mechanisms of endocrine and metabolic diseases.
Assessments every 2 years
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Chongqing Medical University
Chongqing, China
Actively Recruiting
Loading map...
Research Team
Q
Qifu Li, MD, PhD, Chief Physician
S
Shumin Yang, MD, PhD, Chief Physician
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
cAMP-MicroRNA-203-IFNγ network regulates subcutaneous white fat browning and glucose tolerance.
Xiaolong Guo, Zhichun Zhang, Ting Zeng...
https://pubmed.ncbi.nlm.nih.gov/31327757MicroRNA regulatory networks in human adipose tissue and obesity.
Peter Arner, Agné Kulyté
https://pubmed.ncbi.nlm.nih.gov/25732520Guidelines for primary aldosteronism: uptake by primary care physicians in Europe.
Paolo Mulatero, Silvia Monticone, Jacopo Burrello...
https://pubmed.ncbi.nlm.nih.gov/27607462Primary Aldosteronism in Patients in China With Recently Detected Hypertension.
Zhixin Xu, Jun Yang, Jinbo Hu...
https://pubmed.ncbi.nlm.nih.gov/32327102Perirenal Fat Thickness Is Significantly Associated With the Risk for Development of Chronic Kidney Disease in Patients With Diabetes.
Xiangjun Chen, Yun Mao, Jinbo Hu...
https://pubmed.ncbi.nlm.nih.gov/34593536Abdominal Obesity Is More Closely Associated With Diabetic Kidney Disease Than General Obesity.
Jinbo Hu, Shumin Yang, Aipin Zhang...
https://pubmed.ncbi.nlm.nih.gov/27538755Weight Change, Lifestyle, and Mortality in Patients With Type 2 Diabetes.
Jinbo Hu, Yang Hu, Ellen Hertzmark...
https://pubmed.ncbi.nlm.nih.gov/34741524Association of nut consumption with total and cause-specific mortality.
Ying Bao, Jiali Han, Frank B Hu...
https://pubmed.ncbi.nlm.nih.gov/24256379Curbing the Diabetes Pandemic: The Need for Global Policy Solutions.
Frank B Hu, Ambika Satija, JoAnn E Manson
https://pubmed.ncbi.nlm.nih.gov/25996138